Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug

[1]  Y. Ichinose,et al.  S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[2]  N. Izumi,et al.  [A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[3]  H. Nagai,et al.  [A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[4]  Y. Furuta,et al.  [Long-term complete response to treatment with TS-1 in a patient with oropharyngeal squamous cell carcinoma]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[5]  S. Kudoh,et al.  Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer , 2001, International Journal of Clinical Oncology.

[6]  S. Kudoh,et al.  Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer , 2001, British Journal of Cancer.

[7]  R. Diasio,et al.  Clinical implications of dihydropyrimidine dehydrogenase inhibition. , 1999, Oncology.

[8]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[9]  A. Fujioka,et al.  Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. , 1996, Cancer research.

[10]  Handra,et al.  COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER , 2001 .